| CAS NO: | 485395-71-9 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 485395-71-9 |
| 别名 | AHGDM |
| Canonical SMILES | O=C(C(NCCCCCCN)=C1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(C)/[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(C)\C2=O)C=C(N2)C1=O |
| 分子式 | C34H52N4O8 |
| 分子量 | 644.8 |
| 溶解度 | DMSO: 200 mg/mL (310.17 mM) |
| 储存条件 | -20°C, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities[1]. HPMA copolymer-aminohexylgeldanamycin conjugates target cell surface expressed GRP78 in prostate cancer[2]. [1]. Greish K, et al. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release. 2011;151(3):263-270. [2]. Larson N, et al. HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer. Pharm Res. 2010;27(12):2683-2693. |
m.cnreagent.com